The treatment of cancer-associated venous thromboembolic disease is complex due to an increased risk of thrombotic recurrence and bleeding under treatment. During the first 6 months, low molecular...

Risk of venous thromboembolism (VTE) is elevated in cancer and leads to high morbidity and mortality in this population. Drug prophylaxis is questionable, due hemorrhagic risk in these patients,...